Evidence map›Paper›PMID 35175470›Full record

ArticleBulletin of experimental biology and medicine2022

Genetic Markers of Therapeutic Efficacy of Methotrexate in Patients with Psoriasis.

O E Voron'ko, K K Baskaev, V V Sobolev, E V Denisova, I M Korsunskaya

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Biomedicines · 2023
    Article
  2. Pharmaco-Omics in Psoriasis: Paving the Way towards Personalized Medicine.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

O E Voron'koV. N. Orekhovich Research Institute of Biomedical Chemistry, Moscow, Russia.
K K BaskaevV. N. Orekhovich Research Institute of Biomedical Chemistry, Moscow, Russia.
V V SobolevCenter for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences, Moscow, Russia. vlsobolew@gmail.com.
E V DenisovaCenter for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences, Moscow, Russia.
I M KorsunskayaCenter for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences, Moscow, Russia.
Center for Theoretical Problems of Physicochemical Pharmacology · RUInstitute of Biomedical Chemistry · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We studied the effect of C677T and A1298C polymorphisms of the MTHFR gene and 2R/3R polymorphisms of the TYMS gene on the sensitivity to methotrexate in patients with psoriasis (n=139). It was shown that genotype 3R/3R TYMS (OR 8.86, 95%CI 2.00-39.22) and complex genotypes MTHFR1298:A;TYMS:3R (OR 8.20, 95%CI 2.36-28.48) and MTHFR677:C;TYMS:3R (OR 5.40, 95%CI 1.95-14.94) were associated with sensitivity to methotrexate, while genotype 2R/2R TYMS (OR 8.20, 95%CI 2.36-28.48) and complex genotypes MTHFR1298:C;MTHFR677:T;TYMS:2R (OR 0.18, 95%CI 0.06-0.56) and MTHFR1298:C;MTHFR677:T (OR 0.23, 95%CI 0.09-0.59) were associated with resistance to methotrexate. The results can be used for preventive assessment of the effectiveness of methotrexate treatment in patients with psoriasis.

Indexed as

MethotrexatePsoriasisGenetic MarkersGenotypeHumansMethylenetetrahydrofolate Reductase (NADPH2)Thymidylate SynthaseGenetic MarkersMethotrexateMethylenetetrahydrofolate Reductase (NADPH2)Thymidylate Synthasegenetic markersmethotrexatemethylenetetrahydrofolate reductase (MTHFR)psoriasisthymidylate synthase

Identifiers

PMID35175470
OpenAlexW4213288815

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.